Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash to Debt No Debt
SRDX's Cash to Debt is ranked higher than
97% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.97 vs. SRDX: No Debt )
Ranked among companies with meaningful Cash to Debt only.
SRDX' s Cash to Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Equity to Asset 0.80
SRDX's Equity to Asset is ranked higher than
80% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. SRDX: 0.80 )
Ranked among companies with meaningful Equity to Asset only.
SRDX' s Equity to Asset Range Over the Past 10 Years
Min: 0.74  Med: 0.92 Max: 0.95
Current: 0.8
0.74
0.95
Interest Coverage No Debt
SRDX's Interest Coverage is ranked higher than
95% of the 125 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 83.10 vs. SRDX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
SRDX' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 5
Z-Score: 8.53
M-Score: -2.47
WACC vs ROIC
7.62%
18.58%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 23.62
SRDX's Operating margin (%) is ranked higher than
91% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.98 vs. SRDX: 23.62 )
Ranked among companies with meaningful Operating margin (%) only.
SRDX' s Operating margin (%) Range Over the Past 10 Years
Min: -25.85  Med: 29.47 Max: 47.31
Current: 23.62
-25.85
47.31
Net-margin (%) 13.99
SRDX's Net-margin (%) is ranked higher than
88% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.37 vs. SRDX: 13.99 )
Ranked among companies with meaningful Net-margin (%) only.
SRDX' s Net-margin (%) Range Over the Past 10 Years
Min: -30.17  Med: 17.25 Max: 30.9
Current: 13.99
-30.17
30.9
ROE (%) 10.07
SRDX's ROE (%) is ranked higher than
71% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.20 vs. SRDX: 10.07 )
Ranked among companies with meaningful ROE (%) only.
SRDX' s ROE (%) Range Over the Past 10 Years
Min: -12.91  Med: 10.43 Max: 23.9
Current: 10.07
-12.91
23.9
ROA (%) 8.42
SRDX's ROA (%) is ranked higher than
83% of the 215 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.94 vs. SRDX: 8.42 )
Ranked among companies with meaningful ROA (%) only.
SRDX' s ROA (%) Range Over the Past 10 Years
Min: -11.85  Med: 8.38 Max: 19.94
Current: 8.42
-11.85
19.94
ROC (Joel Greenblatt) (%) 86.61
SRDX's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 215 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -11.88 vs. SRDX: 86.61 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SRDX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -27.6  Med: 78.06 Max: 110.87
Current: 86.61
-27.6
110.87
Revenue Growth (3Y)(%) 12.30
SRDX's Revenue Growth (3Y)(%) is ranked higher than
77% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.50 vs. SRDX: 12.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SRDX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -24.6  Med: 15.45 Max: 57.9
Current: 12.3
-24.6
57.9
EBITDA Growth (3Y)(%) -4.70
SRDX's EBITDA Growth (3Y)(%) is ranked lower than
60% of the 128 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. SRDX: -4.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SRDX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -32.7  Med: 16 Max: 90.6
Current: -4.7
-32.7
90.6
EPS Growth (3Y)(%) -8.40
SRDX's EPS Growth (3Y)(%) is ranked lower than
60% of the 119 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.00 vs. SRDX: -8.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SRDX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -35.4  Med: 11.8 Max: 48.3
Current: -8.4
-35.4
48.3
» SRDX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

SRDX Guru Trades in Q4 2015

Paul Tudor Jones 10,829 sh (New)
Jim Simons 754,938 sh (+18.88%)
Mario Gabelli 90,548 sh (unchged)
Chuck Royce 523,200 sh (-8.88%)
Mairs and Power 20,825 sh (-31.92%)
» More
Q1 2016

SRDX Guru Trades in Q1 2016

Paul Tudor Jones 14,561 sh (+34.46%)
Mario Gabelli 107,548 sh (+18.77%)
Jim Simons 832,138 sh (+10.23%)
Chuck Royce 576,600 sh (+10.21%)
Mairs and Power 16,700 sh (-19.81%)
» More
Q2 2016

SRDX Guru Trades in Q2 2016

Jim Simons 850,538 sh (+2.21%)
Mario Gabelli 107,548 sh (unchged)
Chuck Royce 502,600 sh (-12.83%)
Paul Tudor Jones 12,206 sh (-16.17%)
Mairs and Power 11,700 sh (-29.94%)
» More
Q3 2016

SRDX Guru Trades in Q3 2016

Jim Simons 860,138 sh (+1.13%)
Mario Gabelli 106,048 sh (-1.39%)
Mairs and Power 10,338 sh (-11.64%)
Paul Tudor Jones 9,647 sh (-20.97%)
Chuck Royce 328,092 sh (-34.72%)
» More
» Details

Insider Trades

Latest Guru Trades with SRDX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NAS:OXFD, NYSE:ENZ, NAS:ONVO, NAS:LNTH, NAS:RDNT, NAS:TRIB, AMEX:SENS, NYSE:NVTA, NAS:TTOO, NAS:HSKA, NAS:NVDQ, NAS:NRCIA, NAS:CTSO, NAS:PMD, NAS:QTNT, AMEX:VNRX, NAS:BEAT, OTCPK:EPGNF, NAS:TROV, NAS:CEMI » details
Traded in other countries:SU6.Germany,
SurModics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry.

SurModics Inc was organized as a Minnesota corporation in June 1979. The Company is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. Its business units are organized and managed in two reportable segments, Medical Device and In Vitro Diagnostics. The core offerings in its Medical Device business unit include surface modification coating technologies that impart lubricity, prohealing or biocompatibility characteristics, or drug delivery capabilities. It manufactures or sells components for in vitro diagnostic immunoassay and molecular tests and it manufactures and sells surface coatings to the diagnostic, biomedical research, and life science markets. The In Vitro Diagnostics products include Protein Stabilizers, Substrates, Recombinant Human Antigens, and Surface Coatings for Molecular Diagnostic Applications.

Ratios

vs
industry
vs
history
P/E(ttm) 31.67
SRDX's P/E(ttm) is ranked lower than
51% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.23 vs. SRDX: 31.67 )
Ranked among companies with meaningful P/E(ttm) only.
SRDX' s P/E(ttm) Range Over the Past 10 Years
Min: 8.52  Med: 29.19 Max: 584.75
Current: 31.67
8.52
584.75
Forward P/E 81.30
SRDX's Forward P/E is ranked lower than
93% of the 40 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.19 vs. SRDX: 81.30 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 31.67
SRDX's PE(NRI) is ranked lower than
51% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.23 vs. SRDX: 31.67 )
Ranked among companies with meaningful PE(NRI) only.
SRDX' s PE(NRI) Range Over the Past 10 Years
Min: 8.52  Med: 28.75 Max: 584.75
Current: 31.67
8.52
584.75
Price/Owner Earnings (ttm) 20.51
SRDX's Price/Owner Earnings (ttm) is ranked higher than
69% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.10 vs. SRDX: 20.51 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
SRDX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 13.81  Med: 37.37 Max: 714.12
Current: 20.51
13.81
714.12
P/B 2.90
SRDX's P/B is ranked higher than
57% of the 190 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.41 vs. SRDX: 2.90 )
Ranked among companies with meaningful P/B only.
SRDX' s P/B Range Over the Past 10 Years
Min: 0.98  Med: 3.11 Max: 7.42
Current: 2.9
0.98
7.42
P/S 4.42
SRDX's P/S is ranked lower than
64% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. SRDX: 4.42 )
Ranked among companies with meaningful P/S only.
SRDX' s P/S Range Over the Past 10 Years
Min: 2.17  Med: 5.3 Max: 13.75
Current: 4.42
2.17
13.75
PFCF 23.06
SRDX's PFCF is ranked higher than
50% of the 62 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.06 vs. SRDX: 23.06 )
Ranked among companies with meaningful PFCF only.
SRDX' s PFCF Range Over the Past 10 Years
Min: 9.39  Med: 21.45 Max: 503.11
Current: 23.06
9.39
503.11
POCF 16.99
SRDX's POCF is ranked higher than
54% of the 82 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.55 vs. SRDX: 16.99 )
Ranked among companies with meaningful POCF only.
SRDX' s POCF Range Over the Past 10 Years
Min: 6  Med: 17.41 Max: 30.12
Current: 16.99
6
30.12
EV-to-EBIT 15.60
SRDX's EV-to-EBIT is ranked higher than
66% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.61 vs. SRDX: 15.60 )
Ranked among companies with meaningful EV-to-EBIT only.
SRDX' s EV-to-EBIT Range Over the Past 10 Years
Min: -44.3  Med: 15.55 Max: 243.4
Current: 15.6
-44.3
243.4
EV-to-EBITDA 12.79
SRDX's EV-to-EBITDA is ranked higher than
62% of the 106 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.28 vs. SRDX: 12.79 )
Ranked among companies with meaningful EV-to-EBITDA only.
SRDX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -146.2  Med: 13.3 Max: 108.9
Current: 12.79
-146.2
108.9
Shiller P/E 44.48
SRDX's Shiller P/E is ranked lower than
62% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 37.25 vs. SRDX: 44.48 )
Ranked among companies with meaningful Shiller P/E only.
SRDX' s Shiller P/E Range Over the Past 10 Years
Min: 17.08  Med: 41.68 Max: 132.12
Current: 44.48
17.08
132.12
Current Ratio 5.78
SRDX's Current Ratio is ranked higher than
85% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. SRDX: 5.78 )
Ranked among companies with meaningful Current Ratio only.
SRDX' s Current Ratio Range Over the Past 10 Years
Min: 1.77  Med: 4.9 Max: 14.42
Current: 5.78
1.77
14.42
Quick Ratio 5.42
SRDX's Quick Ratio is ranked higher than
85% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. SRDX: 5.42 )
Ranked among companies with meaningful Quick Ratio only.
SRDX' s Quick Ratio Range Over the Past 10 Years
Min: 1.69  Med: 4.5 Max: 13.79
Current: 5.42
1.69
13.79
Days Inventory 110.68
SRDX's Days Inventory is ranked lower than
58% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 89.17 vs. SRDX: 110.68 )
Ranked among companies with meaningful Days Inventory only.
SRDX' s Days Inventory Range Over the Past 10 Years
Min: 33.96  Med: 117.73 Max: 188.8
Current: 110.68
33.96
188.8
Days Sales Outstanding 35.13
SRDX's Days Sales Outstanding is ranked higher than
87% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.99 vs. SRDX: 35.13 )
Ranked among companies with meaningful Days Sales Outstanding only.
SRDX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 30.19  Med: 38.53 Max: 80.51
Current: 35.13
30.19
80.51
Days Payable 51.77
SRDX's Days Payable is ranked lower than
54% of the 157 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 59.52 vs. SRDX: 51.77 )
Ranked among companies with meaningful Days Payable only.
SRDX' s Days Payable Range Over the Past 10 Years
Min: 33.07  Med: 46.81 Max: 166.09
Current: 51.77
33.07
166.09

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 2.10
SRDX's 3-Year Average Share Buyback Ratio is ranked higher than
92% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.50 vs. SRDX: 2.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SRDX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -5.1  Med: 0.9 Max: 8.1
Current: 2.1
-5.1
8.1

Valuation & Return

vs
industry
vs
history
Price/Net Cash 14.85
SRDX's Price/Net Cash is ranked lower than
52% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 12.60 vs. SRDX: 14.85 )
Ranked among companies with meaningful Price/Net Cash only.
SRDX' s Price/Net Cash Range Over the Past 10 Years
Min: 5.81  Med: 30.42 Max: 107.95
Current: 14.85
5.81
107.95
Price/Net Current Asset Value 9.53
SRDX's Price/Net Current Asset Value is ranked higher than
50% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.20 vs. SRDX: 9.53 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SRDX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 4.38  Med: 15.09 Max: 119.54
Current: 9.53
4.38
119.54
Price/Tangible Book 5.37
SRDX's Price/Tangible Book is ranked lower than
56% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.64 vs. SRDX: 5.37 )
Ranked among companies with meaningful Price/Tangible Book only.
SRDX' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.26  Med: 4.42 Max: 12.02
Current: 5.37
1.26
12.02
Price/Projected FCF 1.26
SRDX's Price/Projected FCF is ranked higher than
72% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.97 vs. SRDX: 1.26 )
Ranked among companies with meaningful Price/Projected FCF only.
SRDX' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.53  Med: 1.53 Max: 7.45
Current: 1.26
0.53
7.45
Price/Median PS Value 0.84
SRDX's Price/Median PS Value is ranked higher than
66% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.03 vs. SRDX: 0.84 )
Ranked among companies with meaningful Price/Median PS Value only.
SRDX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.44  Med: 1.29 Max: 5.9
Current: 0.84
0.44
5.9
Price/Graham Number 2.73
SRDX's Price/Graham Number is ranked higher than
57% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.92 vs. SRDX: 2.73 )
Ranked among companies with meaningful Price/Graham Number only.
SRDX' s Price/Graham Number Range Over the Past 10 Years
Min: 0.9  Med: 2.88 Max: 10.54
Current: 2.73
0.9
10.54
Earnings Yield (Greenblatt) (%) 6.40
SRDX's Earnings Yield (Greenblatt) (%) is ranked higher than
84% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. SRDX: 6.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SRDX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.4  Med: 5.8 Max: 22
Current: 6.4
0.4
22
Forward Rate of Return (Yacktman) (%) 27.34
SRDX's Forward Rate of Return (Yacktman) (%) is ranked higher than
84% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.71 vs. SRDX: 27.34 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
SRDX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 1.6  Med: 3.8 Max: 36.4
Current: 27.34
1.6
36.4

More Statistics

Revenue (TTM) (Mil) $71.37
EPS (TTM) $ 0.75
Beta0.70
Short Percentage of Float5.75%
52-Week Range $17.45 - 30.75
Shares Outstanding (Mil)13.05

Analyst Estimate

Sep17 Sep18
Revenue (Mil $) 66 71
EPS ($) 0.30 0.32
EPS w/o NRI ($) 0.30 0.32
EPS Growth Rate
(3Y to 5Y Estimate)
15.00%
Dividends Per Share ($)
» More Articles for NAS:SRDX

Headlines

Articles On GuruFocus.com
SurModics Inc. Reports Operating Results (10-Q) Aug 06 2010 
SurModics Inc. Reports Operating Results (10-Q) May 07 2010 
SurModics Inc. Reports Operating Results (10-Q) Feb 05 2010 
SurModics Inc. Reports Operating Results (10-K) Dec 11 2009 
SurModics Inc. (SRDX) Senior VP & CFO Philip D Ankeny sells 5,000 Shares Oct 08 2009 
SurModics Inc. Reports Operating Results (10-Q) Aug 07 2009 
SurModics Inc. Reports Operating Results (10-Q) May 08 2009 
SurModics Inc. Reports Operating Results (10-Q) Feb 09 2009 

More From Other Websites
SURMODICS INC Files SEC form 8-K, Change in Directors or Principal Officers Nov 28 2016
SurModics, Inc. :SRDX-US: Earnings Analysis: Q4, 2016 By the Numbers : November 23, 2016 Nov 23 2016
Surmodics to Attend Piper Jaffray Healthcare Conference Nov 22 2016
Surmodics downgraded by Barrington Research Nov 21 2016
SurModics (SRDX) Beats Q4 Earnings & Revenues Estimates Nov 17 2016
Edited Transcript of SRDX earnings conference call or presentation 16-Nov-16 1:30pm GMT Nov 17 2016
Surmodics Reports Fourth Quarter Fiscal 2016 Results Nov 16 2016
SurModics posts 4Q profit Nov 16 2016
SurModics posts 4Q profit Nov 16 2016
SURMODICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 16 2016
Surmodics Reports Fourth Quarter Fiscal 2016 Results Nov 16 2016
Q4 2016 Surmodics Inc Earnings Release - Before Market Open Nov 16 2016
ETFs with exposure to SurModics, Inc. : November 15, 2016 Nov 15 2016
SurModics, Inc. breached its 50 day moving average in a Bullish Manner : SRDX-US : November 14, 2016 Nov 14 2016
Surmodics to Present at Canaccord Genuity Medical Technology and Diagnostics Forum Nov 09 2016
Surmodics to Webcast Fourth Quarter and Fiscal Year 2016 Earnings Conference Call on November 16 Nov 08 2016
Surmodics to Webcast Fourth Quarter and Fiscal Year 2016 Earnings Conference Call on November 16 Nov 08 2016
SURMODICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a... Nov 07 2016
ETF’s with exposure to SurModics, Inc. : November 1, 2016 Nov 01 2016
Surmodics Announces Launch of Serene® Single-Coat (SC) Solutions Offering Unmatched Lubricity and... Oct 31 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)